Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830542 · ClinicalTrials.gov registry record · Phase 1
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1 study, sponsored by Seres Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02830542: Completed Phase 1 study, sponsored by Seres Therapeutics.
NCT02830542 is a Phase 1 study that has completed, run by Seres Therapeutics. The registered enrollment target is 96 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02830542, a Phase 1 study, has completed, sponsored by Seres Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of investigational drug versus placebo in adults with primary (first episode) Clostridium difficile infection (CDI).
Interventions
- DRUG Placebo
- DRUG SER-262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
What the finished NCT02830542 record still lists
NCT02830542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02830542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02830542 about?
NCT02830542 is a clinical study titled "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence". The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of investigational drug versus placebo in adults with primary (first episode...
What is the current status of trial NCT02830542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2016-08. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02830542?
The interventions under investigation include: Placebo (DRUG), SER-262 (DRUG).
Who is sponsoring clinical trial NCT02830542?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02830542's enrollment target sits among peer trials
96 600th of 2000 higher than 1,391 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia